Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Q-VD-OPh is a potent, cell-permeable, and irreversible broad-spectrum caspase inhibitor. It is designed to inhibit a wide range of caspases, including caspase-1, -3, -7, -8, -9, -10, and -12, thereby effectively blocking the apoptotic cell death pathway. Compared to earlier generation inhibitors like Z-VAD-FMK, Q-VD-OPh demonstrates significantly higher potency, superior stability, and markedly reduced cellular toxicity, making it a preferred tool compound for both in vitro and in vivo research. It is frequently utilized in studies to distinguish between different modalities of cell death, such as apoptosis and ferroptosis, and to investigate the role of caspases in neurodegeneration, inflammation, and oncology. Notably, Q-VD-OPh does not inhibit other proteases like calpains or cathepsins at concentrations that fully suppress caspase activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Q-VD-OPh.